banner

The official advocacy organization for pharmacist women in the United States

Advertisement

Pharmacist Moms Group

45,000+ Members

45,000+ Members

Over 6 Million posts, comments and reactions in 2020

Over 6 Million posts, comments and reactions in 2020

60,000+ Followers on social media platforms

60,000+ Followers on social media platforms

The Largest Community of Women Pharmacists in the US

pharmacist moms

Founded in 2017, Pharmacists Moms Group was created to provide women pharmacists the opportunity to network, collaborate and offer genuine feedback in a closed-door, trusted setting. The organization has quickly grown to over 45,000 members and 60,000 followers on our social media platforms.

Pharmacy News
View More
ImCheck’s ICT01 Earns FDA Orphan Drug Designation for AML

ImCheck's ICT01 gains an orphan drug designation from the FDA, offering hope for acute myeloid leukemia (AML) treatment in older patients with limited options.

Polypurine Hairpin Technology is Safe, Effective at Inhibiting PCSK9 to Regulate Cholesterol

Researchers unveil a groundbreaking method using polypurine hairpins to inhibit PCSK9, offering a promising alternative for lowering cholesterol and reducing cardiovascular risk.

Study Suggests Transplant Recipients Are at Greater Risk of Developing RSV

Immunocompromised patients, especially transplant recipients, face heightened RSV risks, leading to severe infections and complications.

NCCN Flash Update: Updated CML Guidelines Emphasize Distress Screening, Drug Interactions, and Cost

The updated version 1.2026 NCCN Guidelines for chronic myeloid leukemia (CML) emphasize individualized treatment strategies, TKI-specific considerations, drug interaction management, and pregnancy safety, highlighting the critical role of oncology pharmacists in optimizing therapy selection, patient counseling, and cost-effective care.

NCCN Flash Update: Linvoseltamab Added as Preferred Regimen After 4 Prior Therapies for Multiple Myeloma

The National Comprehensive Cancer Network (NCCN) has released multiple myeloma guidelines version 2.2026 to include linvoseltamab as a preferred treatment for heavily pretreated patients, highlighting its intravenous formulation, dosing options, and streamlined Risk Evaluation and Mitigation Strategy program.

NCCN Flash Update: Ovarian Cancer Guidelines Version 3.2025 Released With Maintenance Therapy Adjustment for HR-Deficiency

The National Comprehensive Cancer Network (NCCN) has updated its ovarian cancer guidelines version 3.2025 to recommend niraparib as maintenance therapy for patients with BRCA wild-type or homologous recombination (HR)–deficiency who did not receive bevacizumab during primary treatment.

Advertisement
Advertisement

Official Media Partner

Official Media Partner

Official CE Partner

Official CE Partner

Founder of Women Pharmacist Day

Founder of Women Pharmacist Day
pharmacist moms group logo
Stay In Touch
an mjh life sciences brand

© 2021 MJH Life Sciences and Pharmacy Times®. All rights reserved.

Privacy Policy